Sanofi to Present New Data of its Neurology Portfolio at MSVirtual2020

Shots:

• Sanofi Genzyme reports the new data from the company’s neurology portfolio, to be presented at MSVirtual2020. The company will highlight new data on tolebrutinib (SAR442168), supporting its potential in modulating disabling inflammatory processes within the CNS and will provide a deeper understanding of Sanofi Genzyme’s current MS therapies and pipeline products
• Additionally, the company will present posters and platform presentations highlighting the studies assessing the safety, efficacy, and investigational uses of approved therapies Aubagio (teriflunomide) and Lemtrada (alemtuzumab) reinforcing the consistent, positive clinical profiles of two treatment options
• Tolebrutinib is an investigational BTK inhibitor and has demonstrated BTK binding as well as cerebrospinal fluid exposure in P-I studies. Teriflunomide is a prescription medicine used to treat RMS including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults

Click here ­to­ read full press release/ article | Ref: Sanofi | Image: UPI